A novel oral GnRH antagonist, elagolix, is effective for reducing endometriosis-associated pelvic pain: results of a 24-week randomized study
OA: bronze
CC0
⤵ 4 in-corpus citations
AI-generated summary
Elagolix, a novel oral GnRH antagonist, effectively reduced endometriosis-associated pelvic pain over 24 weeks in a randomized study.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
My notes (saved in your browser only)
Condition tags
Citation neighborhood (sparse)
Too few in-corpus citations on either side for a chart; here are the lists.
Cited by (4)
- Elagolix, an oral GnRH antagonist, versus subcutaneous depot medroxyprogesterone acetate for the treatment of endometriosis: effects on bone mineral density 2014
- Elagolix treatment for endometriosis-associated pain: results from a phase 2, randomized, double-blind, placebo-controlled study 2013
- Elagolix, a novel, orally bioavailable GnRH antagonist under investigation for the treatment of endometriosis-related pain 2015
- Overview of elagolix for the treatment of endometriosis 2016
Cited by (4)
- Overview of elagolix for the treatment of endometriosis 2016
- Elagolix, a novel, orally bioavailable GnRH antagonist under investigation for the treatment of endometriosis-related pain 2015
- Elagolix, an oral GnRH antagonist, versus subcutaneous depot medroxyprogesterone acetate for the treatment of endometriosis: effects on bone mineral density 2014
- Elagolix treatment for endometriosis-associated pain: results from a phase 2, randomized, double-blind, placebo-controlled study 2013
Source provenance
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0
· commercial use OK